<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622267</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 20-2571</org_study_id>
    <nct_id>NCT04622267</nct_id>
  </id_info>
  <brief_title>Barbed Suture for Hysterotomy Closure During Cesarean Section</brief_title>
  <official_title>Barbed Suture: A Look at Its Use for Hysterotomy Closure During Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial. The purpose of this study is to see if patients whose&#xD;
      uterine incision (hysterotomy), at the time of scheduled cesarean section, is closed with&#xD;
      barbed suture, have less blood loss compared to women whose incision is closed with the&#xD;
      standard suture (vicryl). The primary outcome is quantification of blood loss (QBL).&#xD;
      Secondary outcomes include time for hysterotomy closure, need for additional hemostatic&#xD;
      sutures, rate of endometritis, use of hemostatic agents, and differences in pain which will&#xD;
      be assessed by a telephone screening in the days following delivery.&#xD;
&#xD;
      Study participation will last 1 year and will include the following research procedures :&#xD;
&#xD;
        1. Randomization to barbed suture vs. standard suture&#xD;
&#xD;
        2. Collection of data for primary and secondary outcomes&#xD;
&#xD;
        3. Telephone survey 2 weeks following the procedure to assess pain, bowel/bladder habits,&#xD;
           and evidence of wound infection. The barbed suture is approved by the FDA for use in&#xD;
           soft tissue approximation and this is not an off-label usage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized controlled trial (RCT) evaluating whether using a barbed&#xD;
      suture to close a C-section incision can reduce blood loss. Patients undergoing C-section&#xD;
      will be randomized with equal allocation to a barbed suture or a standard antimicrobial&#xD;
      suture. The primary outcome is quantification of blood loss (QBL). Differences between the&#xD;
      groups will be assessed using a 0.05 level Wilcoxon rank-sum test. Secondary outcomes include&#xD;
      time for hysterotomy closure, need for additional hemostatic sutures, rate of&#xD;
      endometritis/SSI (superficial wound infection, deep wound infection, and endometritis) within&#xD;
      6 weeks postpartum, use of hemostatic agents, and differences in pain which will be assessed&#xD;
      by a telephone screening in the days following delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned to either the treatment arm or control arm of the study prior to commencement of the cesarean section and following informed consent. Allocation will be concealed to all researchers/providers until this point. The patients will be randomly allocated by block randomization. Generation of random sequence will be done by independent personnel, usually a statistician, who is not going to be involved in the conduct of the RCT. The access to this sequence should be restricted to only a few individuals who absolutely need to have access.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative blood loss</measure>
    <time_frame>Day 1, At delivery</time_frame>
    <description>Quantification of blood loss (QBL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for hysterotomy closure</measure>
    <time_frame>Day 1, At delivery</time_frame>
    <description>Time for hysterotomy closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who need additional hemostatic sutures</measure>
    <time_frame>Day 1, At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hemostatic sutures</measure>
    <time_frame>Day 1, At delivery</time_frame>
    <description>Number of hemostatic sutures needed during procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Surgical Site Infections (SSI)</measure>
    <time_frame>Day 1, At delivery</time_frame>
    <description>Rate of SSI (any of superficial wound infection, deep wound infection, and endometritis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Surgical Site Infections (SSI)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Rate of SSI (any of superficial wound infection, deep wound infection, and endometritis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain score</measure>
    <time_frame>Day 1, At delivery and 2 weeks</time_frame>
    <description>Change in pain score at 2 weeks from baseline. Pain score from 0 to 10, with higher score indicating more pain.&#xD;
Follow up pain assesment by a telephone screening 2 weeks following delivery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Hysterotomy</condition>
  <arm_group>
    <arm_group_label>Standard suture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard antimicrobial suture (vicryl) - control arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Barbed suture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Barbed suture type is STRATAFIX Symmetric PDS Plus Knotless Tissue</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Barbed suture</intervention_name>
    <description>to close a C-section incision</description>
    <arm_group_label>Barbed suture</arm_group_label>
    <other_name>STRATAFIX Symmetric PDS Plus Knotless Tissue</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard antimicrobial suture</intervention_name>
    <description>to close a C-section incision</description>
    <arm_group_label>Standard suture</arm_group_label>
    <other_name>vicryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients undergoing a scheduled primary cesarean section at Mount Sinai Hospital&#xD;
&#xD;
          -  age 18-64.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multifetal gestations&#xD;
&#xD;
          -  Placenta previas&#xD;
&#xD;
          -  Pre-term patients&#xD;
&#xD;
          -  Patients with prior uterine incisions or a coagulopathy (DIC, Von Willebrands Disease,&#xD;
             etc)&#xD;
&#xD;
          -  Patients undergoing an unplanned or emergency cesarean section&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women are the only subjects eligible for this study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciana Vieira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayisha B Buckley, MD</last_name>
    <phone>954-816-8864</phone>
    <email>Ayisha.buckley@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keisha Paul, MS</last_name>
    <phone>516-967-2738</phone>
    <email>keisha.paul@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayisha B Buckley, MD</last_name>
      <phone>954-816-8864</phone>
      <email>ayisha.buckley@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Luciana Vieira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pfuntner A, Wier LM, Stocks C. Most Frequent Procedures Performed in U.S. Hospitals, 2010: Statistical Brief #149. 2013 Feb. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-. Available from http://www.ncbi.nlm.nih.gov/books/NBK132428/</citation>
    <PMID>23596641</PMID>
  </reference>
  <reference>
    <citation>Greenberg JA, Goldman RH. Barbed suture: a review of the technology and clinical uses in obstetrics and gynecology. Rev Obstet Gynecol. 2013;6(3-4):107-15. Review.</citation>
    <PMID>24920976</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Luciana Vieira</investigator_full_name>
    <investigator_title>Assistant Professor, Obstetrics, Gynecology and Reproductive Science</investigator_title>
  </responsible_party>
  <keyword>Barbed suture</keyword>
  <keyword>Blood loss</keyword>
  <keyword>Hysterotomy</keyword>
  <keyword>Cesarean section</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

